Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin

BACKGROUND: Selecting patients with ‘sufficient life expectancy’ for Phase I oncology trials remains challenging. The Royal Marsden Hospital Score (RMS) previously identified high-risk patients as those with ⩾2 of the following: albumin <35 g l(−1); LDH > upper limit of normal; >2 metastati...

Descripción completa

Detalles Bibliográficos
Autores principales: Ploquin, A, Olmos, D, Lacombe, D, A'Hern, R, Duhamel, A, Twelves, C, Marsoni, S, Morales-Barrera, R, Soria, J-C, Verweij, J, Voest, E E, Schöffski, P, Schellens, J H, Kramar, A, Kristeleit, R S, Arkenau, H-T, Kaye, S B, Penel, N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461164/
https://www.ncbi.nlm.nih.gov/pubmed/22910320
http://dx.doi.org/10.1038/bjc.2012.371

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461164/
https://www.ncbi.nlm.nih.gov/pubmed/22910320
http://dx.doi.org/10.1038/bjc.2012.371

Ejemplares similares